
## Dr. Hui Lyu Assistant Professor of Research

## Education

| Hunan Medical University, Changsha, China  | M.D.                     | 2002 | Clinical medicine    |
|--|--------------------------|------|----------------------|
| Cancer Research Institute of Central South University, Changsha, China                         | M.S.                     | 2005 | Multidrug resistance |
| Department of Pathology, Xiangya school of medicine, Central South University, Changsha, China | Ph.D.                    | 2010 | Pathology            |
| Department of Pathology, University of Colorado<br>Denver, Aurora, CO                          | Postdoctoral<br>Training | 2018 | Cancer Biology       |



Dr. Lyu's research projects focus on breast cancer biology and treatment. During her time with the Cancer Research Institute of Central South University, Dr. Lyu explored the role of the BCRP gene in the development of resistance to chemotherapy in breast cancer. As a postdoctoral fellow in the Department of Pathology at University of Colorado, she studied the molecular mechanisms of HER2/HER3 receptors-mediated resistance to commonly used therapeutics, such as trastuzumab and paclitaxel, in breast cancer treatment.

Since joining LSU Health New Orleans, Dr. Lyu has investigated the role of histone deacetylate (HDAC) inhibitor (HDACi) in regulation of HER3 expression via miRNA-dependent mechanisms in HER2-positive and triple negative breast cancer (TNBC) cells.